- Home
- CTRI vs ETNB Comparison
CTRI vs ETNB Comparison
Compare CTRI & ETNB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CTRI
- ETNB
- Stock Information
- Founded
- CTRI 1909
- ETNB 2018
- Country
- CTRI United States
- ETNB United States
- Employees
- CTRI N/A
- ETNB N/A
- Industry
- CTRI
- ETNB Biotechnology: Pharmaceutical Preparations
- Sector
- CTRI
- ETNB Health Care
- Exchange
- CTRI Nasdaq
- ETNB Nasdaq
- Market Cap
- CTRI 1.8B
- ETNB 1.5B
- IPO Year
- CTRI 2024
- ETNB 2019
- Fundamental
- Price
- CTRI $20.42
- ETNB $10.08
- Analyst Decision
- CTRI Hold
- ETNB Strong Buy
- Analyst Count
- CTRI 7
- ETNB 8
- Target Price
- CTRI $19.00
- ETNB $26.43
- AVG Volume (30 Days)
- CTRI 908.3K
- ETNB 2.2M
- Earning Date
- CTRI 07-28-2025
- ETNB 08-04-2025
- Dividend Yield
- CTRI N/A
- ETNB N/A
- EPS Growth
- CTRI N/A
- ETNB N/A
- EPS
- CTRI 0.00
- ETNB N/A
- Revenue
- CTRI $2,659,287,000.00
- ETNB N/A
- Revenue This Year
- CTRI $5.94
- ETNB N/A
- Revenue Next Year
- CTRI $5.40
- ETNB N/A
- P/E Ratio
- CTRI $4,514.00
- ETNB N/A
- Revenue Growth
- CTRI N/A
- ETNB N/A
- 52 Week Low
- CTRI $14.46
- ETNB $4.16
- 52 Week High
- CTRI $26.84
- ETNB $11.84
- Technical
- Relative Strength Index (RSI)
- CTRI N/A
- ETNB 57.88
- Support Level
- CTRI N/A
- ETNB $9.66
- Resistance Level
- CTRI N/A
- ETNB $10.58
- Average True Range (ATR)
- CTRI 0.00
- ETNB 0.55
- MACD
- CTRI 0.00
- ETNB -0.09
- Stochastic Oscillator
- CTRI 0.00
- ETNB 58.39
About CTRI Centuri Holdings Inc. Common Stock
Centuri Holdings Inc is a pure-play North American utility infrastructure services company that partners with regulated utilities to maintain, upgrade and expand the energy network that powers millions of homes and businesses. Its service offerings primarily consist of the modernization of utility infrastructure through the maintenance, retrofitting and installation of electric and natural gas distribution networks to meet current and future demands while also preparing systems for the transition to clean energy sources. They operate under two primary lines of business which includes Gas Utility Services and Electric Utility Services it is also their two reportable segments as well.
About ETNB 89bio Inc.
89bio Inc is a United States-based clinical-stage biopharmaceutical company focused on the development and commercialization of therapies for the treatment of liver and cardio-metabolic diseases. Its product candidate, pegozafermin (previously BIO89-100), a specifically engineered glycoPEGylated analog of fibroblast growth factor 21 (FGF21), is currently being developed for the treatment of nonalcoholic steatohepatitis (NASH) and for the treatment of severe hypertriglyceridemia (SHTG).